several enhancers and suppressors of the SCA1 phenotype (Fernandez-Funez et al., 2000) . Among the SCA1 modifiers identified by this screen were genes encoding components of protein folding and clearance pathways, as well as genes involved in transcriptional regulation, RNA binding, and nuclear localization.
Thus, studies utilizing both mouse and fly models point to nuclear import, gene expression, and protein folding and clearance as processes that impact on SCA1 pathogenesis. It is likely that the effects of many of the modifiers would depend on interactions between ataxin-1 and other proteins that might involve residues outside of the polyglutamine tract. Protein phosphorylation is a prominent mechanism by which protein/protein interactions, including those involving nuclear transport and degradation, are regulated (Hunter, 2000). To assess whether phosphorylation has a role in regulating ataxin-1's function and pathogenicity, we examined the phosphorylation status of ataxin-1 and found that the serine at residue 776 (S776) was a site of phosphorylation. Importantly, neuronal dysfunction is dramatically dampened in mice expressing an SCA1 transgene encoding ataxin-1 with an expanded polyglutamine tract in which S776 was replaced by an alanine. These results, along with those presented in the paper by Chen et al. Figure 3A depicts the immunization and subsequent purification scheme utilized to obtain the antibody designated PN1168. The specificity of PN1168 was verified by Western blot analyses. Reactivity of PN1168 to ataxin-1 decreased dramatically upon replacing S776 with an Ala (Figure 3B ), and thus this antibody requires the presence of a Ser at position 776 for it to react with ataxin-1. Recognition of ataxin-1 by PN1168 was not affected by replacing the Ser at 780 with an Ala or by substituting a Thr for the Lys at position 772 ( Figure 3B) . However, the recognition of ataxin-1-S776 by PN1168 was decreased substantially by the pretreatment of immune-purified ataxin-1 with phosphatase ( Figure 3C ). These results show that PN1168 is specific for a phospho-Ser at position 776 of ataxin-1.
Immunohistochemical analyses of cerebellar sections from SCA1 transgenic mice were used to assess the subcellular localization of S776-phosphorylated ataxin-1 in vivo. In both ataxin-1[30Q] and ataxin-1[82Q] transgenic mice, Purkinje cell nuclei showed the strongest pattern of staining for ataxin-1 with the 11750 antibody. In these mice, ataxin-1 was also readily detected with the 11750 antibody in the cell bodies and throughout the dendrites of the Purkinje cells ( Figures 4A and 4C) . Reactivity with the phospho-specific antibody PN1168 was also most abundant in the nuclei of Purkinje cells in both ataxin-1[30Q] and ataxin-1[82Q] transgenic mice and detectable to a much lesser extent in Purkinje cell bodies ( Figures 4B and 4D) . Interestingly, the Purkinje cell dendrites showed no reactivity with the PN1168 antibody. Cerebellar sections from SCA1 mice expressing ataxin-1[82Q]-T772 in which the NLS was mutated (K772T) were also examined. In this instance, ataxin-1[82Q]-T772 localized predominantly to the cytoplasm of the cell body and throughout the dendritic tree but was minimally reactive with the phospho-S776-ataxin-1 antibody ( Figures 4E and 4F ). Endogenous murine ataxin-1 was visible in the Purkinje cell nuclei, cell cell pathology were detected in sections examined from mutational mechanism, however, a central issue has an A776 homozygous mouse. Thus, increasing the exbeen discovering the molecular mediator of toxicity in pression of the A776 transgene to a level above that this class of disease: is it the expanded polyglutamine seen in B05 (tg/ϩ) resulted in the appearance of Purkinje tract per se, is it the expanded tract within the host cell pathology. However, the severity of pathology in the protein, or is it the host protein, which becomes particu-32-week-old A776 tg/tg mouse was considerably less than larly toxic due to an altered conformation engendered that seen in B05 tg/ϩ mice at 27 weeks or 18 weeks of by the expanded tract? age (Clark et al., 1997) .
Studies in cell culture, invertebrate, and mouse models have clearly shown that a polyglutamine peptide is quite toxic to cells and causes progressive phenotypes Discussion and cell death. Yet, there is evidence suggesting that host protein sequences, outside of the glutamine tract, Expansion of a glutamine tract is clearly the initiating impact on the course of disease. A polyglutamine pepevent in the pathogenesis of polyglutamine neurodegenerative disorders like SCA1. Since the discovery of this tide is often much more toxic than one flanked by se- and Schuell). The membrane was subjected to autoradiography to for 60 min. To quantify the amount of purified protein, the intensity determine the amount of 33 P incorporation. Following autoradiograof the ataxin-1 bands were compared with the intensity of the known phy, the membrane was subjected to Western blot analysis using concentrations (0.1 g, 0.2 g, 0.5 g, and 1 g) of the 100 kDa band the anti-polyglutamine antibody 1C2 (Chemicon) to normalize for of the BenchMark protein ladder (Invitrogen). Ataxin-1-containing the amount of ataxin-1 in each sample. In the case of ataxin-1 with bands that had an intensity of at least 0.1 g per band were excised 30 glutamines, we probed the membrane with anti-ataxin-1 11750 and stored at Ϫ20ЊC. We repeated the immunoprecipitation protocol (Servadio et al., 1995) . and pooled approximately 50 g immune-purified ataxin-1. Tryptic digestion and sequence analysis was performed at the Harvard Microchemistry Facility. This analysis consisted of microcapillary Characterization of an Ataxin-1 S776 Phospho-Specific reverse-phase HPLC nano-electrospray tandem mass spectrometry Antibody (PN1168) on a Finnigan LCQ quadruple ion trap mass spectrometer.
The ataxin-1 S776 phospho-specific antibody was generated and affinity purified by New England Peptide (Fitchburg, MA). Briefly, the S776 phosphorylated peptide (see Figure 3 ) was used to immuCell Transfections, Protein Analysis, and Immunofluorescence nize two rabbits. Serum collected from these rabbits was passed over an affinity column that had the unphosphorylated form of the COS1 cells growing on 60 mm dishes were transiently transfected using Effectene (Qiagen) as per the manufacturer's recommended immunizing peptide bound to the matrix. The flowthrough from this column was passed over a second column that had the phosphoryprotocol. Forty-eight hours posttransfection, cells were washed in PBS and lysed in 0.5 ml lysis buffer (50 mM Tris-Cl [pH 7.5], 2.5 mM lated immunizing peptide bound to the matrix. The eluent from this column was designated antibody PN1168. MgCl 2 , 100 mM NaCl, 0.5% Triton X-100, 1ϫ protease inhibitors [Roche Biochemicals], phosphatase inhibitor cocktails I and II The specificity of PN1168 was assessed by treating immunoprecipitated ataxin-1 with shrimp alkaline phosphatase (USB). COS1 [Sigma]). The cells were lysed on the plates by rocking at 4ЊC on ice for 15 min. The DNA in the lysate was sheared by passing the cells were transiently transfected with pCDNA-ataxin-1[82Q] and labeled with 33 P-orthophosphate and immunoprecipitated as delysate through a 21-gauge syringe ten times followed by a 25-gauge syringe five times. The lysate was cleared by centrifugation at 14,000 scribed above using 500 l lysis buffer (50 mM Tris-Cl [pH 7.5], 2.5 mM MgCl 2 , 100 mM NaCl, 0.5% Triton X-100, 1ϫ protease inhibitors rpm for 10 min at 4ЊC. The protein concentration was determined using protein assay dye reagent (Bio-Rad). Twenty micrograms of 
